← All trials
NCT07191899
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 5, 2025
- Primary completion
- Dec 30, 2026
- Completion date
- Dec 30, 2027
- First posted
- Sep 25, 2025
- Last posted
- Sep 25, 2025
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alphamab Co., Ltd.Lead sponsor
- Bengbu Medical CollegeOfficial
- Jiao Tong UniversityOfficial
- Central South UniversityOfficial
- Luoyang third people's HospitalOfficial
- Henan Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.